Spark Therapeutics Inc. (NASDAQ:ONCE) traded up 9.3% during mid-day trading on Thursday . The company traded as high as $64.90 and last traded at $63.93, with a volume of 483,642 shares trading hands. The stock had previously closed at $58.49.

A number of equities research analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on Spark Therapeutics in a research note on Tuesday, July 12th. They set an “outperform” rating and a $70.00 price target for the company. Zacks Investment Research upgraded Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a research note on Thursday. Cantor Fitzgerald reiterated a “buy” rating and set a $94.00 price objective on shares of Spark Therapeutics in a research note on Thursday. Jefferies Group reiterated a “hold” rating on shares of Spark Therapeutics in a research note on Sunday, June 12th. Finally, Cowen and Company reiterated a “buy” rating and set a $75.00 price objective on shares of Spark Therapeutics in a research note on Thursday, May 19th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $61.20.

The firm’s market cap is $1.70 billion. The company has a 50-day moving average price of $54.70 and a 200-day moving average price of $41.73.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by $0.07. The firm earned $1.29 million during the quarter, compared to analysts’ expectations of $1.17 million. During the same period last year, the firm posted ($0.60) EPS. The firm’s revenue was up .0% on a year-over-year basis. Equities analysts anticipate that Spark Therapeutics Inc. will post ($3.81) earnings per share for the current year.

In other news, Director Anand Mehra sold 500 shares of the firm’s stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $60.00, for a total value of $30,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 25,000 shares of the firm’s stock in a transaction dated Thursday, May 19th. The stock was sold at an average price of $46.01, for a total value of $1,150,250.00. Following the completion of the transaction, the chief executive officer now owns 255,000 shares of the company’s stock, valued at $11,732,550. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Spark Therapeutics stock. RS Investment Management Co. LLC boosted its stake in Spark Therapeutics Inc. (NASDAQ:ONCE) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 452,349 shares of the company’s stock after buying an additional 9,957 shares during the period. RS Investment Management Co. LLC owned 1.83% of Spark Therapeutics worth $20,496,000 as of its most recent SEC filing.

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.